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Abstract. It has been shown previously that a novel nitro-
oxy derivative of celecoxib exerts antiproliferative and pro-
apoptotic effects in human colon cancer cells. The aim of this
study was to elucidate whether these biological properties
depend on COX-2 inhibition and/or NO release. Therefore,
the derivative was decomposed into the parent compound
celecoxib and the NO donor benzyl nitrate and the biological
role of each was tested in COX-2-positive (HT-29) and 
-negative (SW-480) colon cancer cells. The main findings
were that the nitro-oxy derivative behaved like celecoxib in
HT-29 cells in terms of COX-2 and ERK/MAPK inhibition,
as well as induction of apoptosis, while the benzyl nitrate
had no such effects. Interestingly, the β-catenin system was
activated by the nitro-oxy derivative as well as by benzyl
nitrate alone more potently than by the parent compound
celecoxib, suggesting a possible regulatory role for NO. In
SW480 cells, these activities were substantially less
pronounced, suggesting the presence of COX-2-dependent
mechanisms in the modulation of these parameters.
Epidemiological, animal and cell culture studies have widely
shown chemopreventive and tumour-regressive effects of
non-steroidal anti-inflammatory drugs (NSAIDs) on
colorectal cancer and several other tumour types (1, 2). The
antiproliferative effects of NSAIDs are, at least partially,
attributed to their cyclooxygenase (COX) inhibitory activity
(3). Two isoforms of COX are recognized, of which COX-1
is expressed constitutively, while COX-2 is inducible at sites
of inflammation and tissue repair. Furthermore, COX-2
expression is high in many types of cancer and increases
early on during colon carcinogenesis (4), and COX-2 derived
prostaglandins are able to promote tumour growth by
accelerating cellular proliferation, inhibiting apoptosis and
enhancing metastasis and angiogenesis (5). 
Thus, selective inhibition of the COX-2 isoenzyme offers
a useful drug design concept that results in the development
of effective anti-inflammatory drugs devoid of the adverse
gastrointestinal and/or cardiovascular toxicity associated with
the use of traditional NSAIDs (6). Unfortunately, selective
COX-2 inhibitors such as celecoxib and rofecoxib alter the
natural balance in the COX pathway (7), decreasing the
amount of the desirable vasodilatory and anti-aggregatory
prostacyclin while simultaneously increasing the level of the
undesirable prothrombotic thromboxane A2 (8-9).
Based on the observation that nitric oxide (NO) possesses
some of the same useful pharmacological properties as
prostaglandins within the gastric mucosa, such as vascular
relaxation and inhibition of platelet activation, a new class
of coxibs able to release NO has been synthesized (10). NO
donor coxib may thus represent a novel approach to reducing
the side-effects of coxibs, especially their gastric and
cardiovascular toxicity (10).
NO-coxibs consist of a known coxib molecule and an NO-
releasing group (typically -NO2) linked to it via a chemical
spacer. This coupling might deliver NO to the site of coxib-
induced damage and thus reduce gastric toxicity. Existing
data, mostly from animal studies, indicate that this
hypothesis may be true (11).
Among NO-donor coxibs, a series of nitro-oxy methyl
substituted derivatives of celecoxib that present one or two
nitro-oxy functions on the phenyl rings have been studied.
These new compounds are able to inhibit the COX-2 enzyme
and are capable of dilating rat aorta strips precontracted with
phenylephrine in an NO-dependent manner (10). In a
previous study, it was demonstrated that in HT-29 colon
cancer cells celecoxib and its nitro-oxy derivatives induced a
significant reduction of cell growth; a reduction that was
accompanied by the inhibition of the ERK-MAPK cascade,
the induction of apoptosis and the modulation of the 
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E-cadherin/β-catenin system. Among these derivatives, the
compound with two nitro-oxy functions was the most
effective in affecting the parameters that were studied,
raising the question of whether NO may be required for this
modulation (12).
Therefore, given the structural complexity of this molecule,
this study decomposes the compound’s two nitro-oxy functions
into the parent compound celecoxib and the NO donor benzyl
nitrate in order to gain insight into the contribution of the NO
donor to the known activities of celecoxib (Figure 1). The
effects of celecoxib, a nitro-oxy derivative of celecoxib and
benzyl nitrate on a number of cellular responses including
proliferation, apoptosis, activation of ERK and PI3K pathways,
invasion and translocation of β-catenin from the nucleus to the
plasma membrane were compared on HT-29 and SW-480
human colon cancer cell lines. 
Materials and Methods
Reagents. Celecoxib, a nitro-oxy derivative of celecoxib and benzyl
nitrate were a gift from the laboratory of Professor Gasco,
Department of Scienza e Tecnologia del Farmaco, University of
Torino, Italy (10). The drugs were solubilized in dimethylsulfoxide
(DMSO) (Sigma Chemical Co, Saint-Louis, USA) and freshly
diluted in culture medium before each experiment. The final DMSO
concentration never exceeded 0.1% and this condition was used as
a control in each experiment.
Rabbit polyclonal antibody specific for pAkt, ERK1, gp91-phox,
bak and procaspase-3, mouse monoclonal antibody specific for β-
catenin, caspase-3, PI3-kinase p85α, Akt and pERK1/2, goat anti-
rabbit and goat anti-mouse secondary antibodies were obtained from
Santa Cruz Biotechnology, Inc (CA, USA). Rabbit polyclonal
antibody specific for COX-2 was from Cayman Chemical (Michigan,
USA). Enhanced chemiluminescence detection system was obtained
from Amersham Pharmacia Biotech (Uppsala, Sweden). Mouse
monoclonal antibody specific for β-actin and all other reagents were
purchased from Sigma Chemical Co (Saint Louis, MO, USA). 
Cell culture. HT-29 and SW-480 human colon cancer cell lines were
obtained from the American Type Cell Collection (Manassas, VA,
USA). The cells were grown and maintained in McCoy’s 5A (HT-
29) and DMEM (SW-480) medium supplemented with 10% foetal
bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 25
μg/ml amphotericin B. Cells were cultured at 37˚C in a humidified
incubator with 5% CO2 and 95% air, and examined regularly using
an inverted microscope. 
For the experiments, cells were seeded at a density of 3×104
cells/cm2 and cultured for 24 h to allow them to adhere to the
substratum and then treated with the drugs or DMSO. 
Viability assay. Cell viability was assessed by the trypan blue
exclusion assay. Aliquots of cell suspension were incubated with
trypan blue solution for 5 min. Finally, cells were transferred to a
Bürker chamber and counted by light microscope. Dead cells were
defined as those stained with the dye. 
Protein extraction. Total extracts: Collected cells were suspended
in lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM
ethylenediaminetetraacetic acid (EDTA), 0.1 mM phenylmethyl-
sulfonyl fluoride (PMSF), 0.05% aprotinin, 0.1% Igepal) and then
incubated for 30 min at 4˚C. The suspension was centrifuged for 25
min at 12000 rpm and the supernatant from this centrifugation was
saved as the total extracts. 
Nuclear extracts: Collected cells were suspended in lysis buffer
(10 mM Hepes-NaOH pH 7.8, 10 mM KCl, 2 mM MgCl2, 1 mM
dithiothreitol (DTT), 0.1 mM EDTA, and 0.1 mM PMSF) and then
incubated for 15 min at 4˚C. After addition of 10% (v/v) Nonidet
P-40, the cell suspension was mixed, incubated for 30 min at 4˚C,
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Figure 1. Molecular structure of celecoxib, its nitro-oxy derivative and
benzyl nitrate.
and centrifuged for 15 min at 3000 rpm. The pellet was resuspended
in lysis buffer (50 mM Hepes-NaOH pH 7.8, 50 mM KCl, 300 mM
NaCl, 0.1 mM EDTA, 1 mM DTT, 0.1 mM PMSF and 10% v/v
glycerol). The suspension was mixed for 30 min at 4˚C and
centrifuged for 15 min at 3000 rpm; the supernatant from this
centrifugation was saved as the nuclear extract.
Membrane-associated fractions: Collected cell were suspended in
hypotonic buffer (10 mM Tris pH 7.4, 0.2 mM MgCl2, 2 μg/ml
pepstatin A, 2 μg/ml leupeptin and 100 μg/ml PMSF) for 10 min on
ice and then homogenised with a Dounce homogeniser. The
homogenates were centrifuged for 37 min at 20750 rpm; the
resulting precipitate was analysed as a membrane-associated fraction.
Western blotting. Protein contents in the supernatants were measured
using a commercially available assay (Bio-Rad, Hercules, CA, USA)
with bovine serum albumin as a standard. Extracts were then
subjected to sodium dodecyl sulphate-polyacrylamide gel
electrophoresis on 12, 10 or 7.5% acrylamide gels. The blots were
incubated with desired primary antibodies and then incubated with
peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulins in
Tris-buffered saline-Tween containing 2% (wt/vol) non-fat dry milk,
and developed with the enhanced chemiluminescence reagents. Band
intensities were quantified by densitometry and the expression of
proteins was reported as a proportion of β-actin, ERK1, Akt or gp91-
phox protein expression to monitor any discrepancies in gel loading
(VersaDoc Imaging System 3000; Bio-Rad). 
Fluorescence microscopy. The cells were fixed and permeabilized
for 20 min at –20˚C with methanol/acetone (1:1) and were
incubated with anti-β-catenin primary antibody followed by anti-
mouse Cy3-conjugated secondary antibody. Then the cells were
stained with 4’,6-diamidino-2-phenylindole (DAPI, 1 mg/ml in
methanol) for 30 min at 37˚C to detect nuclei. After washing with
PBS, slides were mounted with H2O/glycerol (1:1) and viewed
under a fluorescence microscope equipped with a UV light filter
(Dialux 20; Leitz, Wetzlar, Germany).
Invasion assay. Invasion was evaluated with Boyden chambers
equipped with 8-μm porosity polyvinylpyrrolidone-free polycarbonate
filters that were coated with 50 μg/ml of Matrigel solution.
Invasiveness was quantified by counting crystal violet-stained cells
that invaded Matrigel using a Zeiss microscope (Oberkochen,
Germany) equipped with bright-field optics (×40). For each
filter/Matrigel, the number of cells in ten randomly chosen fields was
counted, and the counts were averaged (means±SD). Results are
expressed as the number of migrated cells per high-power field.
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Figure 2. Effect on cell growth, ERK phosphorylation state, PI3K/Akt pathway and apoptotic features. HT-29 cells were incubated for 24 h with 50
μM celecoxib, 50 μM nitro-oxy derivative, 100 μM benzyl nitrate, alone or in combination with 50 μM celecoxib. Cell viability was determined by
the trypan blue exclusion test (A). Values are represented as a persentage of the control and bars are the means±S.D. from 3 independent experiments.
Statistical significance: *p<0.001 vs untreated control; §p<0.001 vs. d; no statistical significance between all groups. The cells were processed for
Western blot analysis with anti-pERK1/2 (B), -PI3K, -pAkt (C), -bak, -caspase-3 and -procaspase-3 (D) antibodies. Protein content was normalized
with anti-β-actin, ERK1 or Akt antibody and analysed by densitometry. The blots shown are representative of 3 independent experiments.
Gelatinolytic zymography. Conditioned media from the cell cultures
were analysed for gelatin degradation activity by SDS-PAGE under
non-reducing conditions. Samples for analysis were diluted in 1:1
non-reducing buffer (12.5% 0.5M Tris-HCl pH 6.8, 10% glycerol,
4% SDS, and 0.05% bromophenol blue) and then fractionated by
electrophoresis on sodium dodecyl sulfate polyacrylamide gel
electrophoresis co-polymerized with 0.2% gelatin A. After
separation, the gels were washed twice in 2.5% Triton-X 100 for 15
min and incubated in buffer (Tris-HCl 5 mM, CaCl2 10 mM, NaCl
50 mM, pH 7.6) at 37˚C over night. The gelatinolytic activities of
matrix metallopeptidase 2 (72 kDa type IV collagenase, MMP-2)
were visualised by staining the gel with 0.1% Coomassie brilliant
blue and destained with 45% methanol, 10% v/v acetic acid until
clear bands suggestive of gelatin digestion were present. The gels
were washed out with distilled water and scanned for densitometry
(VersaDoc Imaging System 3000; Bio-Rad). 
Statistical analysis. Differences between means were analysed for
significance using the one-way ANOVA test with the Bonferroni
post hoc multiple comparisons being used to assess the differences
between independent groups. All values are expressed as
means±SD, and differences were considered significant at p<0.05.
Results
The contribution of the NO-releasing moiety (-ONO2) to the
biological effects of nitro-oxy derivative of celecoxib in HT-
29 colon cancer cells was analysed. The cells were treated
for 24 h with appropriate concentrations of NO donor benzyl
nitrate alone or in combination with celecoxib (IC50: 51 μM)
to reconstitute the molecular structure of nitro-oxy derivative
(IC50: 40 μM).
For this study, a concentration of 100 μM benzyl nitrate
was chosen since it is comparable to the amount of NO that
is generated from nitro-oxy derivative as confirmed by Griess
reaction (data not shown).
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Figure 3. Effect on expression and intracellular localization of β-catenin. HT-29 cells were treated as described in Figure 1. A: Nuclear and
membrane-associated extracts were probed with anti-β-catenin antibody; protein fractions were normalized with anti-gp91-phox antibody or Ponceau
Red dye and analysed by densitometry. The blots shown are representative of 3 independent experiments. B: The cells were incubated with anti-β-
catenin primary antibody followed by anti-mouse Cy3-conjugated secondary antibody. To detect nuclei the cells were stained with DAPI. The panels
show the overlaid pictures (magnification ×400). The images shown are representative of 3 independent experiments.
Benzyl nitrate alone at 100 μM concentration did not
influence the cell viability rate, while celecoxib, its nitro-oxy
derivative and co-administration of celecoxib (50 μM) and
benzyl nitrate (100 μM) caused a remarkable decrease of the
survival of HT-29 cells (Figure 1A).
Based on the reported ability of celecoxib to inhibit
ERK/MAPK, the effect of nitro-oxy derivative and benzyl
nitrate alone or in combination with celecoxib on the
phosphorylation state of ERK was evaluated. Benzyl nitrate
had no effect on the active form of ERK as the reduction of
ERK phosphorylation occurred only if the NO donor was in
association with celecoxib (Figure 1B).
The PI3-kinase pathway is involved in the regulation of
cell survival and apoptosis, and its activation is associated
with tumour growth and progression (14). In line with the
data regarding ERK phosphorylation, celecoxib, its nitro-oxy
derivative and benzyl nitrate in combination with celecoxib
reduced the expression of both p85α, the regulatory subunit
of PI3-kinase pathway, and phospho-Akt, the downstream
effector of the cascade. Again, the NO donor benzyl nitrate
alone had no effect (Figure 1C).
Akt is overexpressed in several types of cancer; in
particular, in human colon carcinomas the phosphorylation
of Akt is correlated with the induction of cell proliferation
and with the inhibition of apoptosis (14).
As regards the regulation of apoptosis, a significant
reduction of procaspase-3 and a considerable increase of
caspase-3 and bak was seen only when the NO donor was in
association with celecoxib (Figure 1D).
Previous studies evidenced that celecoxib and its nitro-oxy
derivative are able to induce the membrane fraction of β-
catenin/E-cadherin complex (12). To evaluate whether NO
was involved in the regulation of this effect, the expression
of β-catenin protein in HT-29 cells treated with benzyl
Bocca et al: A Novel NO-derivative of Celecoxib Inhibits Colon Cancer Cell Growth
2663
Figure 4. Effect on cell invasion, matrix metalloproteinase activity and COX-2 expression. A: HT-29 cells were incubated for 24 h with 25 μM celecoxib,
25 μM nitro-oxy derivative, 50 μM benzyl nitrate, alone or in combination with 25 μM celecoxib. Matrigel invasion was evaluated by Boyden chamber
assay. Each filter was examined with a Zeiss microscope and the number of cells was counted. Results are expressed as the number of migrated cells
(means) per high-power field. The values represent the mean of 3 independent experiments. Statistical significance: *p<0.01; **p<0.001 vs. untreated
control. HT-29 cells were treated as described in Figure 1. The gelatinolytic activity of MMP-2 was visualized as active (act) MMP-2 of a zymogram,
representative of 3 independent experiments (B). Total cell extracts were processed for Western blot analysis with anti-COX-2 antibody; protein content
was normalized with anti-β-actin antibody and analysed by densitometry. The blots shown are representative of 3 independent experiments (C).
nitrate was also analysed. Immunofluorescence and Western
blot analysis indicated that benzyl nitrate alone was able to
increase the expression of beta-catenin in the membrane
fraction to a greater extent than celecoxib alone. In addition,
the increase was markedly higher in cells exposed to the NO
donor in combination with celecoxib with respect to nitro-
oxy derivative, (Figure 2A, B), suggesting that the NO-
releasing group amplifies the celecoxib effect. In all cases,
the increase of membranous β-catenin levels corresponded
to the reduction of nuclear β-catenin levels (Figure 2A).
An increase of beta-catenin in the membrane fraction
after HT-29 cell treatment with celecoxib and its nitro-oxy
derivative may lead to an increase of cell–cell adhesion
and to a reduction of invasiveness. Thus the ability of these
compounds to reduce colon cancer cell migration was
determined. The classic Boyden chamber assay showed
that all the compounds significantly decreased the ability
of HT-29 cells to invade Matrigel. In addition, the nitro-
oxy derivative showed the highest migration inhibition
(Figure 3A).
To better determine the ability of celecoxib and its
derivative to reduce cell migration, the activity of matrix
metalloproteinase-2 (MMP-2), which is involved in the
breakdown of the basement membrane by extracellular
matrix degradation was also evaluated. The zymogram
showed that celecoxib, its nitro-oxy derivative and benzyl
nitrate in combination with celecoxib reduced the activity of
MMP-2 in the medium supernatant of HT-29 cells. Also in
this case, benzyl nitrate alone was less effective than the
parent compounds (Figure 3B).
Since it has previously been demonstrated that the nitro-oxy
derivative is able to decrease the expression of COX-2, a
classical target of celecoxib, the possible role of the NO-
releasing moiety was evaluated for this effect. Benzyl nitrate
alone did not determine any detectable variation of COX-2
expression, while its co-administration with celecoxib reduced
COX-2 protein levels, thus indicating that the NO-releasing
group is not implicated in COX-2 expression (Figure 3C).
To verify the involvement of COX-2 and the influence of
the NO-releasing group on the effect of the nitro-oxy
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Figure 5. Effect on cell growth, ERK phosphorylation state, PI3K/Akt pathway and apoptotic features. SW-480 cells were incubated for 24 h with
50 μM celecoxib, 50 μM nitro-oxy derivative, 100 μM benzyl nitrate, alone or in combination with 50 μM celecoxib. Cell viability was determined
by the trypan blue exclusion test (A). Values are represented as a persentage of the control and bars are the means±S.D. from 3 independent
experiments. Statistical significance: *p<0.05 vs. untreated control; §p<0.05 vs. d; no statistical significance between groups overall. The cells were
processed for Western blot analysis with anti-pERK1/2 (B), -PI3K, -pAkt (C), and -caspase-3 (D) antibodies. Protein content was normalized with
anti-β-actin, ERK1 or Akt antibody and analysed by densitometry. The blots shown are representative of 3 independent experiments.
derivative the effect of each constituent in a COX-2 non-
expressing SW-480 cell line was also examined.
In these cells, all the compounds that were tested induced
a small decrease in SW-480 cell growth (Figure 4A). In
accordance with the modest effect on cell viability, the
treatment with celecoxib, its nitro-oxy derivative and benzyl
nitrate in combination with celecoxib caused only a weak
decrease of phospho-ERK expression, while benzyl nitrate
alone was ineffective (Figure 4B). The ability to inhibit p85α
and Akt expression was maintained in response to celecoxib,
nitro-oxy derivative and benzyl nitrate in combination with
celecoxib, while NO donor alone did not have any effect
(Figure 4C). In contrast, none of the compounds were able
to interfere with caspase-3 activation, suggesting that the
inhibition of cell growth is not dependent on apoptosis
induction (Figure 4D).
Discussion
Data from a previous study (12) demonstrated that a nitro-
oxy derivative of celecoxib with two NO-releasing moieties
effectively inhibits HT-29 human colon cancer cell growth.
The biological activity seen with this compound can possibly
be ascribed to the presence of a NO releasing moiety in
addition to the COX-2 inhibitory effect. The goal of this
study was to determine the contribution of the NO donor to
the known activities of celecoxib. To evaluate this question
this study assessed the effects of each structural component
of the nitro-oxy derivative on HT-29 human colon carcinoma
cells, which express COX-2, and on SW-480 human colon
carcinoma cells which, in contrast, do not express the
enzyme.
In accordance with literature data (12, 15, 16), the current
data clearly indicate that celecoxib and the nitro-oxy
derivative influence the expression level of cell growth
regulating proteins and apoptosis markers. For instance, Akt
kinase, which is frequently overespressed in tumour cells,
has been found to be inhibited by celecoxib (17). It has been
reported that the blockade of Akt activation depends on
inhibition of the upstream 3-phosphoinositide-dependent
kinase-1 (16) and represents a major molecular mechanism
by which celecoxib induces apoptosis. In line with these
findings, the nitro-oxy derivative was able to inhibit p85α
and Akt kinase with greater potency with respect to benzyl
nitrate alone. In a similar manner, the nitro-oxy derivative
reduced the phosphorylation state of ERK and modulates the
expression of apoptosis regulating proteins.
Several authors have reported that COX-2 expression is
regulated through the activation of ERK, JNK, and p38 in
transformed cells, and that the amount of COX-2 is
significantly decreased by their inhibitors (18-20). In
addition, COX-2 overexpression is reported to be associated
significantly with activated AKT expression, suggesting an
interaction between COX-2 activity and PI3-Kinase/Akt
pathway (21). In accordance with these findings, in this
study it was observed that celecoxib and its derivative
decreased ERK and Akt activation and concomitantly
reduced COX-2 expression. Taken together, these findings do
not evidence a correlation between the presence of the NO-
donating moiety and the ability to inhibit ERK/MAPK and
PI3-kinase/Akt pathways or to induce apoptosis, which seem
rather to be regulated by COX-2-in dependent mechanisms.
This study also showed that treatment of HT-29 human colon
carcinoma cells with celecoxib led to an increment of the
membrane-bound β-cateninn and to a reduction of the
nuclear fraction of β-catenin. Interestingly, both benzyl
nitrate alone and the nitro-oxy derivative induced beta-
catenin protein levels more potently than did celecoxib,
indicating that the NO-releasing moiety is crucial for the
modulation of this pathway.
The up-regulation of the β-catenin system mediated by
celecoxib and its nitro-oxy derivative may suggest
chemopreventive effects of these drugs on colon cancer.
These compounds may reduce the ability of tumour cells to
invade local tissues and to spread to distant sites, either by
reducing the secretion of MMP-2 or by inhibiting the
adhesiveness of colon cancer cells. In this regard, it has been
reported that the inhibition of MMPs exerts a protective
effect on tumour promotion through the regulation of
proinflammatory enzymes, including COX-2 (22). COX-2 is
rapidly induced by growth factors, tumour promoters and
hormones, thus playing an important role in inflammation
and wound healing (23). Overexpression of COX-2
contributes to carcinogenesis by stimulation of cell survival
and angiogenesis (24). From the current results it is,
therefore, conceivable that the NO-releasing moiety is not
crucial for the inhibition of cell invasion, as the NO donor
benzyl nitrate did not influence cell migration and MMP-2
release.
It is not possible to absolutely predict the targets of
celecoxib and the derivative responsible for their
antiproliferative/antitumour activity. However, it was
observed that the cells lacking COX-2 (SW-480) responded
to nitro-oxy derivative in a different manner from HT-29
cells.
In particular, in SW-480 cells the antiproliferative effect
and the inhibition of ERK/MAPK and PI3-kinase/Akt
pathways of nitro-oxy derivative were less effective than
those detected in HT-29 cells. These findings indicate that
the presence of COX-2 is required above all for the growth
inhibitory and pro-apoptotic effects of celecoxib and
derivative on colon cancer cells. On the contrary, the fact that
celecoxib and nitro-oxy derivative were not able to induce
β-catenin expression in SW-480 cells (data not shown)
suggests that this effect may involve both COX-2- and NO-
dependent mechanisms.
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These preliminary data indicate that celecoxib and nitro-
oxy derivative do not block prostaglandin synthesis, at least
at concentrations that inhibit cell growth (data not shown).
This suggests that the effect of nitro-oxy derivative occurs
independently of the cellular COX-2 expression, the classical
target of the selective COX-2 inhibitors.
In conclusion, the current data suggest that celecoxib and
the novel nitro-oxy derivative of celecoxib, which promises
to be less toxic than the parent compound, are equally
effective in HT-29 and SW-480 colon cancer cells. The
structural modifications of celecoxib seem to modify its
antiproliferative activity that in the NO derivative is exerted
through mechanisms independently of (or in addition to) its
COX-2 inhibitory effect.
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